Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-488-2 | CAS number: 96-20-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction: other studies
Administrative data
- Endpoint:
- toxicity to reproduction: other studies
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- 10 May 2006 to 09 August 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP, meets generally accepted scientific standards and methods are well-described
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- No guideline for dose range-finding study to set dose levels for a guideline 2-generation study.
- GLP compliance:
- yes
- Type of method:
- in vivo
Test material
- Reference substance name:
- 4,4-dimethyloxazolidine
- EC Number:
- 257-048-2
- EC Name:
- 4,4-dimethyloxazolidine
- Cas Number:
- 51200-87-4
- IUPAC Name:
- 4,4-dimethyl-1,3-oxazolidine
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Each animal was evaluated by a laboratory veterinarian, or a trained animal/toxicology technician under the direct supervision of a laboratory veterinarian, to determine the general health status and acceptability for study purposes upon arrival at the laboratory (fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International - AAALAC International).
TEST ANIMALS
- Charles River:
- Age at study initiation: 6 wks
- Fasting period before study: No
- Housing: he animals were housed two or three per cage in stainless steel cages, in rooms designed to maintain adequate conditions
- Diet (e.g. ad libitum): Certified Rodent Diet #5002 (PMI Nutrition International, St. Louis, Missouri) in meal form, ad libitum
- Water (e.g. ad libitum): municipal water supply ad libitum
- Acclimation period: minimum 1-week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-1C
- Humidity (%): 40-70%
- Air changes (per hr): 12-15
- Photoperiod (hrs dark / hrs light): 12-h light:dark
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: All dosing solutions were prepared by mixing the test material in PEG 400 at concentrations of 6.25, 18.75, 37.5, or 75 mg/ml
VEHICLE (PEG 400)
- Concentration in vehicle: 6.25, 18.75, 37.5, or 75 mg/ml - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose confirmation analyses of all dose solutions were determined pre-exposure. The homogeneity of the low- and the high-dose solutions was determined concurrent with the dose confirmation. The method for analyzing the test material in PEG 400 was gas chromatography-mass spectrometry (GC/MS) with internal and external standards.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- once daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 25, 75, 150 or 300 mg/kg/day
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
0, 22.8, 74.8, 146, 302 mg/kg/day
Basis:
analytical conc.
- No. of animals per sex per dose:
- 8
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- A cage-side examination was conducted twice daily, preferably at the same time each day, designed to detect significant clinical abnormalities that are clearly visible upon a limited examination, and to monitor the general health of the animals. In addition, all animals were observed for morbidity, mortality, and the availability of feed and water at least twice daily. Clinical examinations were conducted on all animals at least once daily. Animals were observed approximately one hour after dosing. All rats will be weighed pre-exposure, twice during the first week and weekly throughout the study.
Feed consumed was determined twice during the first week and weekly for all animals by weighing feed containers at the start and end of a measurement cycle.
A complete necropsy was conducted on all animals include an examination of the external tissues and all orifices. Weights of the liver and kidneys will be recorded, and organ:body weight ratios calculated. Histologic examination will be conducted on all control and high-dose rats and all animals that die or are sacrificed in a moribund condition. Examination of tissues from the remaining groups will be limited to those tissues that demonstrate treatment-related histologic effects at the high dose and relevant gross lesions. - Statistics:
- Statistical Analyses
Body weights, feed consumption and organ weights (absolute and relative) will first be evaluated by Bartlett's test (alpha = 0.01) for equality of variances. Based upon the outcome of Bartlett's test, either a parametric or nonparametric analysis of variance (ANOVA) will be performed. If the ANOVA is significant at alpha = 0.05, a Dunnett's test (alpha = 0.05) or the Wilcoxon Rank-Sum (alpha = 0.05) test with Bonferroni's correction will be performed. Both the Dunnett's test and Bonferroni's correction correct for multiple comparisons to the control to keep the experiment-wise error rate at 0.05. Both will be reported at the experiment-wise alpha level. Feed consumption values will be excluded from analysis if the feed has been spilled or scratched. Statistical outliers (alpha = 0.02) will be identified by the sequential method of Grubbs (1969). Outliers will only be excluded from analysis for documented, scientifically sound reasons.
If deemed necessary, more statistical tests will be performed. Because numerous measurements will be statistically compared in the same group of animals, the overall false positive rate (Type I errors) will be greater than the nominal alpha levels. Therefore, the final interpretation of the data will consider statistical analyses along with other factors, such as dose-response relationships and whether the results are consistent with other biological and pathological findings and historical control values.
Results and discussion
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 75 mg/kg bw/day
- Sex:
- male
- Basis for effect level:
- other: based on the occurrence of a single rat with slight hepatocellular vacuolization
- Dose descriptor:
- NOEL
- Effect level:
- ca. 25 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: based on effects observed at higher dose levels
Any other information on results incl. tables
Administration of CS-1135 at dose levels of 75, 150, and 300 mg/kg/day resulted in toxicity following 90-days of exposure. Seven animals did not survive to their scheduled necropsies. Four of these deaths were attributed to gavage error. In three high-dose rats, CS-1135 was interpreted to be contributory to the cause of death. Mean body weights of males in all dose levels were slightly lower than controls by 3-10%; however, only the body weight decrement of males given 300 mg/kg/day was interpreted to be treatment related. High-dose males had a lower mean final body weight (9%) that was consistent with their in-life body weights, along with higher relative kidney (10%), and liver weights (15%). Females in the high-dose group had a higher mean relative (15%) liver weight compared to controls that was statistically identified and interpreted to be treatment related.
Lesions
occurred in the nonglandular and glandular portions of the stomach in
numerous males and females given 300 mg/kg/day and fewer males and
females given
150 mg/kg/day. Degenerative
lesions consisted of erosions/ulcers and/or multiple foci of necrosis
and inflammation involving the glandular mucosa and were noted in one
male and a few females given 300 mg/kg/day. Subacute
to chronic inflammation occurred in the submucosa of the glandular
stomach of males and females given 300 mg/kg/day. The
inflammation was focal or multifocal in distribution and varied in
severity from very slight to severe. Similar
inflammatory changes were also observed in the majority of males given
150 mg/kg/day and were focal in distribution, very slight in degree, and
were also interpreted to be treatment related. Diffuse
hyperplasia of the nonglandular stomach was noted in male and female
rats given 150 or 300 mg/kg/day and was dose-related in incidence and
severity (slight to moderate). This
effect was interpreted to be a protective change secondary to irritation
(necrosis and inflammation) induced by CS-1135 and/or its break down
products (i.e., formaldehyde). A
variable number of males treated with 75, 150, or 300 mg/kg/day and one
female given 300 mg/kg/day had very slight to moderate multifocal
vacuolation of hepatocytes that was consistent with fatty change.
The
vaculation was dose related and interpreted to be treatment related.
Two
males and one female given 300 mg/kg/day had either focal or multifocal
hepatocellular necrosis. This
alteration was very slight in degree and was localized to a limited
region of only one of the three liver lobes histologically examined.
Although
the necrosis may be treatment related, it was interpreted to be of
minimal toxicologic significance due to the distribution and limited
parenchyma affected.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.